Get the Stockscreener App
6.83
1.49%
0.10
Fulcrum Therapeutics Inc stock is traded at $6.83, with a volume of 1.01M.
It is up +1.49% in the last 24 hours and down -0.15% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$6.73
Open:
$6.64
24h Volume:
1.01M
Relative Volume:
1.29
Market Cap:
$368.68M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.3228
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-12.55%
1M Performance:
-0.15%
6M Performance:
+72.47%
1Y Performance:
-24.20%
1-Day Range:
$6.56
$7.12
1-Week Range:
$6.50
$8.50
52-Week Range:
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.83 | 363.28M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald - Defense World
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningTrend Confirmation Scanner with Entry Focus - Newser
Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsOversold Opportunity Scanner with RSI Data - Newser
HC Wainwright Issues Positive Estimate for FULC Earnings - Defense World
What is Fulcrum Therapeutics Inc. company’s growth strategyPre Market Forecasts For Smart Trading - jammulinksnews.com
Is Fulcrum Therapeutics Inc. stock ready for a breakoutDaily Investment Ideas with Market Insight - Newser
Are Bears Losing Grip on Fulcrum Therapeutics Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Multi-Year Signal Summary and Entry Timing - Newser
What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Market Forecast Tracker For Smart Trading - jammulinksnews.com
How to interpret RSI for Fulcrum Therapeutics Inc. stockTen-Year Sector Performance and Summary Analysis - Newser
What institutional investors are buying Fulcrum Therapeutics Inc. stockStock Market Forecasts From AI Tools - jammulinksnews.com
What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockPre Market Insights For Beginners - jammulinksnews.com
How many analysts rate Fulcrum Therapeutics Inc. as a “Buy”Wealth Building Picks That Work - jammulinksnews.com
Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN
How strong is Fulcrum Therapeutics Inc. company’s balance sheetEntry Signal Guidance That Work - jammulinksnews.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.29 Consensus Target Price from Brokerages - Defense World
Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsAI Trading Suggestions With Accuracy Focus Released - metal.it
Fulcrum Therapeutics stock price target raised to $5 at RBC Capital - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Buy at HC Wainwright - Defense World
Is Fulcrum Therapeutics Inc. building a consolidation baseTrend Following Ideas with Volume Confirmation - Newser
Published on: 2025-07-30 02:00:45 - Newser
Fulcrum Therapeutics 2024 Q2 Earnings Strong Turnaround with Net Income Swing of 333% - AInvest
Fulcrum defended at H.C. Wainwright post sickle cell disease data - Seeking Alpha
H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data - Investing.com Canada
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment - TipRanks
Fulcrum Therapeutics Inc. Stock Fails to Break Resistance Traders ReactDaily Smart Money Movement Monitor Activated - beatles.ru
Fulcrum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Fulcrum Therapeutics Plunges 29.58% on PIONEER Trial Results - AInvest
Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 1c - StreetInsider
Fulcrum Therapeutics stock falls after sickle cell disease trial results - Investing.com Australia
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics Reports Positive Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative
Fulcrum Therapeutics reports Q2 results, pociredir trial data - StreetInsider
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - Yahoo Finance
Breakthrough Sickle Cell Treatment Achieves 44% Success Rate in Latest Clinical Trial Data - Stock Titan
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionDaily Investment Ideas with Market Insight - Newser
Published on: 2025-07-29 13:21:15 - beatles.ru
Using Ichimoku Cloud for Fulcrum Therapeutics Inc. technicalsDaily Stock Watch Summary with Key Insights - Newser
Fulcrum Therapeutics Soars 16.52% on Sickle Cell Trial Hype - AInvest
Momentum Screeners Rank Fulcrum Therapeutics Inc. in Top 5 TodayWeekly Top Gainers Forecast Watchlist Released - beatles.ru
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics stock soars ahead of sickle cell trial data By Investing.com - Investing.com Canada
Crucial Phase 1b Data Reveals Pociredir's Impact on Sickle Cell Disease at 12mg Dose Level - Stock Titan
Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionGet alerts on high-potential stock breakouts - jammulinksnews.com
Fulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on Wednesday - Defense World
Fulcrum Therapeutics FULC 2025Q2 Earnings Preview Downside Ahead on Analyst Downgrades - AInvest
Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedMaster stock selection with insider knowledge - jammulinksnews.com
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):